Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system
BackgroundTeprotumumab, an IGF-1R monoclonal antibody, has shown significant efficacy in treating thyroid eye disease (TED). However, since teprotumumab was launched in 2020 and first approved in the United States, there were limited reports of post-marketing adverse events (AEs). In this study, we...
I tiakina i:
Ngā kaituhi matua: | , |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
Frontiers Media S.A.,
2024-08-01T00:00:00Z.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ipurangi
Connect to this object online.3rd Floor Main Library
Tau karanga: |
A1234.567 |
---|---|
Tārua 1 | Wātea |